Osteosarcoma Multi-omics
Integrative genomic, transcriptomic, epigenomic, and pharmacologic analysis to reveal therapeutic vulnerabilities and clinically relevant tumor heterogeneity.
Osteosarcoma Mechanisms · Nanomedicine · Multi-omics
LIN QI 戚麟
Specially Appointed Associate Fellow & Postdoctoral Fellow
The Second Xiangya Hospital, Central South University. My research focuses on osteosarcoma pathogenesis, epigenetic regulation of therapy resistance, and precision nanodelivery strategies for cancer intervention.
About
Biography
Lin Qi is a specially appointed associate fellow and postdoctoral fellow at The Second Xiangya Hospital, Central South University.
He received doctoral training in surgery at Central South University and completed joint Ph.D. training in nanomedicine at the National University of Singapore. His work integrates cancer multi-omics, epigenetic regulation, drug-resistance biology, and nanomedicine to identify actionable mechanisms and develop precision delivery strategies for osteosarcoma and related bone and soft-tissue tumors.
20SCI papers as first or corresponding author
3papers in journals with IF > 20
1320+citations
19H-index
Research
Research Interests
Epigenetic Regulation & Drug Resistance
Mechanistic studies of RNA modification, chromatin remodeling, and acetylation programs that shape osteosarcoma progression and chemoresistance.
Precision Nanodelivery Therapy
Carrier-free nano-epidrugs, mRNA therapeutics, and delivery-optimized platforms for targeted intervention in osteosarcoma and cancer therapy.
Publications
Selected Work
2025
Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization
Qi L, Zhang W, Shi C, et al.
Advanced Materials. Nature Index journal, IF 29.4.
2025
Pioneering Next-Generation mRNA Therapeutics through Molecular Engineering and Delivery Optimization
Qi L, Li Z, Feng Z, et al.
Materials Today. IF 26.9.
2025
Cooperative Blockade of FLT3 and ALK Synergistically Suppresses Growth of Osteosarcoma
Zhang W#, Qi L#, Xu H, et al.
Oncogene, 44(7): 427-438.
2024
Omics-Enhanced Nanomedicine for Cancer Therapy
Qi L, Li Z, Liu J, et al.
Advanced Materials, 36(50): 2409102. IF 29.4.
2023
Integrated Multiomic Analysis and High-Throughput Screening Reveal Potential Gene Targets and Synergetic Drug Combinations for Osteosarcoma Therapy
Zhang W#, Qi L#, Liu Z, et al.
MedComm, 4(4): e317.
Projects
Research Projects & Talent Programs
Outstanding Young Talent Program, The Second Xiangya Hospital
Research support for osteosarcoma mechanism discovery and translational nanomedicine.
Hunan Furong Plan Young Talent Program
Young talent program in scientific and technological innovation.
Young Elite Scientists Sponsorship Program, CAST
Doctoral student special program supporting emerging scientific talent.
National Key R&D Program of China
Diagnosis and treatment systems for refractory orthopedic diseases including nonunion and bone infection.
News
Recent Updates
Received the Hunan Furong Plan Young Talent Program.
Joined The Second Xiangya Hospital, Central South University as a specially appointed associate fellow.
Started postdoctoral research at The Second Xiangya Hospital, Central South University.
Published work on carrier-free nano-epidrugs for osteosarcoma chemosensitization in Advanced Materials.
Presented osteosarcoma nano-epidrug research at the 9th Nano Today Conference in Singapore.
Contact
Get in Touch
I welcome conversations with researchers, clinicians, students, and collaborators interested in osteosarcoma biology, cancer multi-omics, epigenetic therapy, and precision nanomedicine.
qi.lin@csu.edu.cn
The Second Xiangya Hospital, Central South University
139 Renmin Middle Road, Changsha, Hunan, China